• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial.

作者信息

Crim Courtney, Anderson Julie A, Calverley Peter M A, Celli Bartolome R, Cowans Nicholas J, Martinez Fernando J, Newby David E, Vestbo Jørgen, Yates Julie C, Brook Robert D

机构信息

GlaxoSmithKline plcResearch Triangle Park, North Carolina.

GlaxoSmithKline plcMiddlesex, United Kingdom.

出版信息

Am J Respir Crit Care Med. 2020 May 15;201(10):1307-1310. doi: 10.1164/rccm.201908-1639LE.

DOI:10.1164/rccm.201908-1639LE
PMID:32017597
Abstract
摘要

相似文献

1
Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial.慢性阻塞性肺疾病中的脉搏波速度及吸入疗法的影响（SUMMIT）：一项随机双盲临床试验
Am J Respir Crit Care Med. 2020 May 15;201(10):1307-1310. doi: 10.1164/rccm.201908-1639LE.
2
Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.中重度气流受限 COPD 患者使用糠酸氟替卡松/维兰特罗吸入剂的肺炎风险：SUMMIT 研究。
Respir Med. 2017 Oct;131:27-34. doi: 10.1016/j.rmed.2017.07.060. Epub 2017 Aug 1.
3
A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.一项关于每日一次糠酸氟替卡松/维兰特罗或维兰特罗与安慰剂对比的随机试验，以确定对慢性阻塞性肺疾病患者动脉僵硬度的影响。
Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:351-365. doi: 10.2147/COPD.S117373. eCollection 2017.
4
Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.吸入性β2受体激动剂/皮质类固醇对心血管高风险慢性阻塞性肺疾病患者心血管结局的影响
Heart. 2017 Oct;103(19):1536-1542. doi: 10.1136/heartjnl-2016-310897. Epub 2017 Apr 17.
5
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.血液嗜酸性粒细胞计数、加重情况以及慢性阻塞性肺疾病患者添加吸入氟替卡松维兰特罗后的反应：两项平行随机对照试验数据的二次分析。
Lancet Respir Med. 2015 Jun;3(6):435-42. doi: 10.1016/S2213-2600(15)00106-X. Epub 2015 Apr 12.
6
Fluticasone-vilanterol combination approved for COPD.氟替卡松-维兰特罗组合药物获批准用于慢性阻塞性肺疾病。
Am J Health Syst Pharm. 2013 Jun 15;70(12):1008. doi: 10.2146/news130042.
7
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.在慢性阻塞性肺疾病中，糠酸氟替卡松/维兰特罗联用乌美溴铵的疗效与安全性：两项随机研究的结果
Respir Med. 2015 Sep;109(9):1155-63. doi: 10.1016/j.rmed.2015.06.006. Epub 2015 Jun 14.
8
Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial.慢性阻塞性肺疾病患者心血管事件的裁定：SUMMIT 试验。
Clin Trials. 2020 Aug;17(4):430-436. doi: 10.1177/1740774520920897. Epub 2020 May 22.
9
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.乌美溴铵对固定气流阻塞且对沙丁胺醇有可逆性患者的肺功能和症状的影响：一项随机、3 期研究。
Respir Med. 2017 Oct;131:148-157. doi: 10.1016/j.rmed.2017.08.013. Epub 2017 Aug 14.
10
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.一项随机、III期试验，比较每日一次糠酸氟替卡松/维兰特罗100/25μg与每日一次维兰特罗25μg，以评估糠酸氟替卡松在慢性阻塞性肺疾病患者联合用药中对肺功能的作用。
Respir Med. 2017 Feb;123:8-17. doi: 10.1016/j.rmed.2016.12.001. Epub 2016 Dec 2.

引用本文的文献

1
Relationship of Lung Function and the Preserved Ratio Impaired Spirometry Pattern with Aortic and Left Ventricular Structure and Function on Magnetic Resonance Imaging: The Jackson Heart Study.肺功能与磁共振成像中肺活量测定模式受损保留率与主动脉及左心室结构和功能的关系：杰克逊心脏研究
Lung. 2025 Mar 20;203(1):51. doi: 10.1007/s00408-025-00808-4.
2
Impact of Spirometrically Confirmed Chronic Obstructive Pulmonary Disease on Arterial Stiffness and Surfactant Protein D After Percutaneous Coronary Intervention. The CATEPOC Study.肺量计确诊慢性阻塞性肺疾病对经皮冠状动脉介入治疗后动脉僵硬度和表面活性蛋白 D 的影响。CATEPOC 研究。
Int J Chron Obstruct Pulmon Dis. 2022 Oct 14;17:2577-2587. doi: 10.2147/COPD.S373853. eCollection 2022.
3
Update in Chronic Obstructive Pulmonary Disease 2020.2020年慢性阻塞性肺疾病的最新进展
Am J Respir Crit Care Med. 2021 Jul 1;204(1):14-22. doi: 10.1164/rccm.202102-0253UP.
4
Cardiovascular and Chronic Obstructive Pulmonary Disease Therapeutics: Two Paths, One Destination?心血管疾病与慢性阻塞性肺疾病治疗：殊途同归？
Am J Respir Crit Care Med. 2020 Sep 1;202(5):779-780. doi: 10.1164/rccm.202004-0982LE.
5
Reply to Fisk and Wilkinson: Aortic Pulse Wave Velocity Predicts All-Cause Mortality in Chronic Obstructive Pulmonary Disease.对菲斯克和威尔金森的回应：主动脉脉搏波速度可预测慢性阻塞性肺疾病的全因死亡率。
Am J Respir Crit Care Med. 2020 Jul 1;202(1):149-150. doi: 10.1164/rccm.202003-0609LE.
6
Aortic Pulse Wave Velocity Predicts All-Cause Mortality in Chronic Obstructive Pulmonary Disease.主动脉脉搏波速度可预测慢性阻塞性肺疾病的全因死亡率。
Am J Respir Crit Care Med. 2020 Jul 1;202(1):148-149. doi: 10.1164/rccm.202002-0329LE.